End-stage Renal Disease
Conditions
Keywords
hemodialysis, renal perfusion, end-stage renal disease
Brief summary
Residual renal function (RRF) characteristically declines after patients with end-stage renal disease (ESRD) initiate dialysis. Although RRF preservation correlates with improved patient's quality of life and survival prospects, poor understanding of the pathophysiology underlying RRF decline limits protection strategies.
Detailed description
Hemodialysis (HD) is the primary renal replacement therapy for patients with end-stage renal disease. However, residual renal function (RRF) characteristically declines after these individuals start dialysis. This loss of RRF not only impacts the adequacy of dialysis and control of complications but also affects the patient's quality of life and survival prospects. Due to a lack of clear understanding regarding the pathophysiology underlying this decline in RRF, no effective strategies exist for its preservation at present. The objective of this study is to explore the changes in renal perfusion during hemodialysis in patients with end-stage renal disease, and provide a new idea for protection of RRF. This study was an observational study, and no interventions were performed.
Interventions
None listed
Sponsors
Yuanjun Yang
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years; * Clinical diagnosis of end-stage renal disease requiring long-term hemodialysis treatment, with dialysis duration ≤ 3 months; * Urine output > 500ml/day or GFR > 3ml/min/1.72m2; * Signed and dated informed consented is obtained.
Exclusion criteria
* Presence of vascular access dysfunction (blood flow rate < 180ml/min); * Severe heart failure; * Active infection; * Infectious disease; * Patients with severe anemia; * Patients with polycystic kidney disease; * Expected dialysis duration < 6 months; * Pregnancy or lactation women; * Patients who are participating in other clinical studies, or who have participated in other clinical studies within 3 months prior to enrollment; * Unwillingness to be followed up or poor adherence to treatment; * Other circumstances that the investigator considers unsuitable for enrolment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| renal perfusion | one day | Changes in renal perfusion during hemodialysis in patients with end-stage renal disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| diastolic blood pressure | one day | diastolic blood pressure during hemodialysis in patients with end-stage renal disease |
| systolic blood pressure | one day | systolic blood pressure during hemodialysis in patients with end-stage renal disease |
| urine volume | 10 months | Urine volume within 10 months of starting dialysis |
Contacts
Primary ContactDayang Xie
Outcome results
None listed